Different patterns of serum interleukin 10 response to treatment with anti-tumor necrosis factor α antibody (infliximab) in Crohn's disease

Physiological Research

Volumn 52, Issue 1, 2003, Pages 95-100

  Detková, Zuzana ^a   Kupcova V ^a   Prikazska M ^a   Turecky L ^a   Weissova S ^a   Jahnova E ^a  

^a Physics and Informatics   (Slovakia)

Author keywords

1 acid glycoprotein; Anti tumor necrosis factor therapy; Crohn's disease; Interleukin 10

Indexed keywords

INFLIXIMAB; INTERLEUKIN 10; OROSOMUCOID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DOWN REGULATION; DRUG INFUSION; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INTESTINE MUCOSA; MALE; OUTCOMES RESEARCH; PARAMETER; PATHOPHYSIOLOGY; SIDE EFFECT; TH1 CELL;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INTERLEUKIN-10; MALE; OROSOMUCOID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037231058     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. BAERT FJ, RUTGEERTS PR: Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications. Int J Colorect Dis 14: 47-51, 1999.
2. BAERT FJ, D'HAENS GR, PEETERS M, HIELE MI, SCHAIBLE TF, SHEALY D, GEBOES K, RUTGEERTS PJ: Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116: 22-28, 1999.
3. BARRAUD B, BALAVOINE S, FELDMANN G, LARDEUX B: Effects of insulin, dexamethasone and cytokines on alpha 1-acid glycoprotein gene expression in primary cultures of normal rat hepatocytes. Inflammation 20: 191-202, 1996.
4. BEST WR, BECKTEL JM, SINGLETON JW: Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI). Gastroenterology 77: 843-846, 1979.
5. BREESE E, BRAEGGER CP, CORRIGAN CJ, WALKER-SMITH JA, MACDONALD TT: Interleukin-2- and interferon-γ-secreting T cells in normal and diseased human intestinal mucosa. Immunology 78: 127-131, 1993.
6. BRIGNOLA C, CAMPIERI M, BAZZOCCHI G, FARRUGGIA P, TRAGNONE A, LANFRANCHI GA: A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 91: 1490-1494, 1986.
7. D'HAENS G, VAN DEVENTER S, VAN HOGERAND, CHALMERS D, KOTHE R, BAERT F, BRAAKMAN T, SCHAIBLE T, GEBOES K, RUTGEERTS P: Endoscopic and histological healing with infliximab anti-TNF antibodies in CD: A European multicenter trail. Gastroenterology 116: 1029-1034, 1999.
8. FIORENTINO DF, ZLOTNIK A, MOSMANN TR, HOWARD M, O'GARRA A: IL-10 inhibits cytokine production by activated macrophages. J Immunol 147: 3815-3822, 1991.
9. FOURNIER T, MEDJOUBI-N N, PORQUET D: Alpha-1-acid glycoprotein. Biochim Biophys Acta 1482:157-171, 2000.
10. KUCHARZIK T, STOLL R, LUGERING N, DOMSCHKE W: Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 100: 452-456, 1995.
11. KUPČOVÁ V, TURECKÝ L, DETKOVÁ Z, PRÍKAZSKÁ M, BÁTOVSKÝ M: Acute phase proteins in Crohn's disease after anti-tumor necrosis factor antibodies treatment. Clin Chem Lab Med 39 (Special Supplement): S341, 2001.
12. LAURELL CB: Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 15: 45-52, 1966.
13. LOUIS E, BELAICHE J, VAN KEMSEKE C, FRANCHIMONT D, DE GROOTE D, GUEENEN V, MARY JY: A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease. Eur J Gastroenterol Hepatol 9: 939-944, 1997.
14. LUBEGA J, DAVIES TJ: A comparison of serum mucoprotein with serum α1 acid glycoprotein, haptoglobin, α1 antitrypsin assays in monitoring inflammatory bowel disease. Clin Chim Acta 188: 59-70, 1990.
15. MCCABE RP, WOODY J, VAN DEVENTER SJH, TARGAN SR, MAYER L, VANHOGEZAND R, RUTGEERTS P, HANAUER SB, PODOLSKY D, ELSON CO: A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease. Gastroenterology 110 (Suppl 4): A962, 1996.
16. MULLIN GE, LAZENBY AJ, HARRIS ML, BAYLESS TM, JAMES SP: Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology 102: 1620-1627, 1992.
17. PLEVY SE, LANDERS CJ, PREHN J, CARRAMANZANA NM, DEEM RL, SHEALY D, TARGAN SR: A role for TNF-α and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 159: 6276-6282, 1997.
18. PULLMAN WE, ELSBURY S, KOBAYASHI M, HAPEL AJ, DOE WF: Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology 102: 529-537, 1992.
19. TARGAN SR, HANAUER SB, VAN DEVENTER SJH, MAYER L, PRESENT DH, BRAAKMAN T, DEWOODY KL, SCHAIBLE TF, RUTGEERTS PJ: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337: 1029-1035, 1997.
20. TAYLOR KD, PLEVY SE, YANG H, LANDERS CJ, BARRY MJ, ROTTER JI, TARGAN SR: ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 120: 1347-1355, 2001.
21. VAN DULLEMEN HM, VAN DEVENTER SJH, HOMMES DW, BIJL HA, JANSEN J, TYTGAT GN, WOODY J: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109: 129-135, 1995.
22. WRIGHT JP, YOUNG GO, TIGLER-WYBRANDI N: Predictors of acute relapse of Crohn's disease. A laboratory and clinical study. Dig Dis Sci 32: 164-170, 1987.